Feasibility study of Nestorone�����ethinylestradiol vaginal contraceptive ring for emergency contraception



      The Nestorone��/ethinylestradiol (NES/EE) vaginal ring is being developed as a regular contraceptive method by the Population Council. This ring is designed to release NES 150 ��g/day and EE 15 ��g/day during 1 year. Here, we report a Phase I clinical trial to determine the usefulness of this ring for emergency contraception. To that end, we tested the ability of this ring to interfere with ovulation when it is inserted during the follicular phase.


      Forty-eight women protected from the risk of pregnancy by nonhormonal methods were divided into three groups, which differed by the size of the dominant follicle at the time of ring insertion: 12���14 mm (n=16), 15���17 mm (n=18) and ���18 mm (n=14) diameter. The NES/EE ring was left in the vagina for 7 consecutive days, after which it was removed. The growth of the leading follicle and plasma levels of estradiol, progesterone (P), luteinizing hormone (LH) and follicle stimulating hormone (FSH) in the ensuing 5 days after ring insertion were determined. Afterwards, steroid hormones were measured twice a week, until menses took place. All women had a control cycle before the ring cycle, and the range of maximum follicular diameter assigned to each volunteer was the same for the control and the ring cycle at the time when placebo was ingested or the ring inserted.


      During the 5-day period after ring insertion with follicles 12���17 mm, ovulation was absent in 25 of 34 cycles (p<.01 vs. control), and ovulatory dysfunction (absent, blunted or mistimed LH peak) occurred in 8 of the 9 remaining cycles (33/34 ovulatory processes altered; p<.005 vs. control). After ring insertion with follicles ���18 mm in diameter, ovulation did not occur in 2 of 14 cycles or was dysfunctional in 7 of the 12 remaining cycles (9/14 ovulatory processes altered; p<.025 vs. control). Altogether, 87.5% of ring cycles (42/48) had either no ovulation or ovulatory dysfunction in the 5-day study period, in contrast to 39.6% (19/48 cycles) in control cycles (p<.001). Among follicles that failed to rupture within the 5-day study period, none ruptured later on in the ring-treated cycles, while 9 of 16 did so in control cycles. Sixty-two percent of ring-treated cycles were shorter than 24 days. Nausea, vaginal discharge and abdominal pain were the most frequently reported adverse events during ring use.


      Interference with 87.5% of ovulatory processes, without ovulation occurring later in the cycle and shortening of cycle length, suggests the NES/EE ring may be used as an emergency contraceptive method, with the potential advantage of providing continuing contraception after it has performed its emergency function.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • World Health Organization
        Task Force on Postovulatory Methods of Fertility Regulation. Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception.
        Lancet. 1998; 352: 428-433
        • Ho P.C.
        • Kwan M.S.
        A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception.
        Hum Reprod. 1993; 8: 389-392
        • Von Hertzen H.
        • Piaggio G.
        • Din J.
        • et al.
        Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial.
        Lancet. 2002; 360: 1803-1810
        • Brache V.
        • Mishell D.R.
        • Lahteenmaki P.
        • et al.
        Ovarian function during use of vaginal rings delivering three different doses of Nestorone.
        Contraception. 2001; 63: 257-261
        • Brache V.
        • Mishell D.R.
        • Moo-Young A.J.
        • et al.
        Ovarian function during use of Nestorone subdermal implants.
        Contraception. 2000; 61: 199-204
        • Kumar N.
        • Koide S.S.
        • Tsong Y.
        • Sundaram K.
        Nestorone: a progestin with a unique pharmacological profile.
        Steroids. 2000; 65: 629-636
        • Croxatto H.B.
        • Brache V.
        • Pavez M.
        • et al.
        Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75 mg dose given on the days preceding ovulation.
        Contraception. 2004; 70: 442-450
        • Wilcox A.J.
        • Weinberg C.R.
        • Baird D.D.
        Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy and sex of the baby.
        N Engl J Med. 1995; 333: 1517-1521
        • Croxatto H.B.
        • Fuentealba B.
        • Brache V.
        • et al.
        Effects of the Yuzpe regimen, given during the follicular phase, on the ovarian function.
        Contraception. 2002; 65: 121-128
        • Hapangama D.
        • Glasier A.F.
        • Baird D.T.
        The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle.
        Contraception. 2001; 63: 123-129
        • Cohlen B.J.
        • te Velde E.R.
        • Scheffer G.
        • et al.
        The pattern of the luteinizing hormone surge in spontaneous cycles is related to the probability of conception.
        Fertil Steril. 1993; 60: 413-417
        • Verpoest W.M.
        • Cahill D.J.
        • Harlow C.R.
        • Hull M.G.
        Relationship between midcycle luteinizing hormone surge quality and oocyte fertilization.
        Fertil Steril. 2000; 73: 75-77
        • Durand M.
        • Cravioto M.C.
        • Raymond E.G.
        • et al.
        On the mechanism of action of short-term levonorgestrel administration in emergency contraception.
        Contraception. 2001; 64: 227-234
        • Brache V.
        • Faundes A.
        • Alvarez F.
        Risk-benefit effects of implantable contraceptives in women.
        Expert Opin Drug Saf. 2003; 2: 321-332
        • Jain J.K.
        • Ota F.
        • Mishell D.R.
        Comparison of ovarian follicular activity during treatment with monthly injectable contraceptive and a low-dose oral contraceptive.
        Contraception. 2000; 61: 195-198